Osiris Therapeutics Regains Worldwide Rights to Prochymal and Chondrogen

Osiris Therapeutics OSIR today announced the conclusion of its collaboration with Genzyme, a Sanofi company. As the Collaboration Agreement is now ended, all rights to Prochymal® and ChondrogenTM worldwide revert back to Osiris. Osiris is now free to commercialize or enter into commercialization agreements for Prochymal and Chondrogen with other parties without limitation. Both parties have agreed to an orderly conclusion of the collaboration, with no further financial responsibilities for either party, and an amicable end to their relationship. Prochymal (remestemcel-L) is a first-in-class mesenchymal stem cell therapy indicated for the treatment of acute graft-vs-host disease (GvHD) in children. In May, Prochymal became the world's first stem See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsGuidanceGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!